Receptor News and Research

RSS

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

16 Dec 2009

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that data presented at a major medical meeting showed that its lead compound GLYX-13 demonstrated robust antidepressant-like and anxiolytic-like activity with no signs of the CNS-related side effects seen with other drugs targeting the NMDA receptor.

16 Dec 2009

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Naurex Inc., a new clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel GFPA NMDA receptor modulators, today announced that it has initiated a Phase I clinical trial of its lead compound GLYX-13 and has successfully dosed the first subjects in the study.

16 Dec 2009

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

16 Dec 2009

Avastin may lose significant patient share to Sanofi-Aventis' BSI-201, according to report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer.

16 Dec 2009

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies.

16 Dec 2009

UCLA researchers find link between brain cancer and fatty acid synthesis

Inhibiting fatty acid synthesis in brain cancer cells may offer a new option to treat about 50 percent of deadly glioblastomas that are driven by amplified signaling of the epidermal growth factor receptor (EGFR), according to a first-of-its-kind study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

16 Dec 2009

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer.

16 Dec 2009

RORalpha protein revealed as an essential regulator of inflammatory factors

How do the brain cells called astrocytes ensure the protection of neurons? By studying the protagonists in the protection and satisfactory functioning of neurons, scientists at the Laboratoire Neurobiologie des Processus Adaptatifs (CNRS/UPMC) have found a mechanism that clarifies the role of astrocytes.

15 Dec 2009

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

15 Dec 2009

AIDS develops more rapidly in individuals who express HLA B*35-Px, shows study

Immune proteins called HLA molecules help to activate killer T cell responses against pathogens. But according to a study that will be published online on December 14th in the Journal of Experimental Medicine (www.jem.org), one particular group of HLA molecules cripples this activation, perhaps explaining why HIV-infected individuals who express these HLAs progress to AIDS more rapidly than others.

15 Dec 2009

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.

14 Dec 2009

Researchers present new data for diagnosis and management of beast cancer

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.

14 Dec 2009

New antibody-drug compound halts growth of metastatic breast tumors

A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.

14 Dec 2009

New biosensors show how schizophrenia drugs alter brain chemistry

Scientists have resolved a question about how a popular class of drugs used to treat schizophrenia works using biosensors that reveal previously hidden components of chemical communication in the brain.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Receptor News and Research

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

FDA Advisory Committee votes against the approval of Tarceva

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

Naurex' GLYX-13 demonstrates antidepressant-like and anxiolytic-like activity without CNS-related side effects

Naurex commences dosing in its GLYX-13 Phase I clinical trial for treatment-resistant depression

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Avastin may lose significant patient share to Sanofi-Aventis' BSI-201, according to report

Scientists rediscover Cyclin G1 gene as prime target for anti-cancer therapies

UCLA researchers find link between brain cancer and fatty acid synthesis

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

RORalpha protein revealed as an essential regulator of inflammatory factors

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

AIDS develops more rapidly in individuals who express HLA B*35-Px, shows study

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Researchers present new data for diagnosis and management of beast cancer

New antibody-drug compound halts growth of metastatic breast tumors

New biosensors show how schizophrenia drugs alter brain chemistry

Pfizer announces results from studies evaluating neratinib

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Texas researchers identify new detection method for circulating tumor cells

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News